Muscle Loss Clinical Trial
Official title:
A Post-marketing, Double-blind, Placebo-controlled, Randomized, Parallel Study to Evaluate the Effect of Dietary Supplement on Muscle Mass and Physical Performance Among People Aged 50 Years and Older
Verified date | April 2021 |
Source | Orient Europharma Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess the ability and safety profile of dietary supplement to augment lean body mass, muscle strength, and physical performance among people aged 50 years and older
Status | Completed |
Enrollment | 80 |
Est. completion date | October 7, 2020 |
Est. primary completion date | October 7, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Main Inclusion Criteria: 1. Male or female aged 50 years or older. 2. Subjects who has muscle loss or at risk of muscle loss, with symptoms of reduced physical activities, reduced gait speed, exhaustion, or had tumbled/ fallen within past year 3. Willing to comply with study procedures and follow-ups 4. Provide written consent Main Exclusion Criteria: 1. Gait speed = 0.3 m/sec 2. Any disease that interferes with limb function, including: 1. Limb fracture within past 6 months 2. Severe knee, hip, or arm arthritis 3. As judged by the investigator, disorder of nervous system (i.e., stroke, severe spinal stenosis, peripheral neuropathy, and Parkinson's disease) with poor control 4. Intermittent claudication due to peripheral artery disease 3. As judged by the investigator, mental disorders (i.e., confirmed diagnosis of dementia) with poor control 4. Cardiopulmonary disease with poor control judged by the investigator 5. Malignancy with poor control judged by the investigator 6. Subjects claim to have chronic renal disease, defined as kidney damage or GFR < 30 mL/min/1.73 m2 for at least 3 months 7. Severe visual and hearing impairment that becomes barrier to communication 8. Subjects have taken any hormone replacement therapy within 3 months prior to study enrollment, or plans to begin hormone replacement therapy at any time during the study 9. Subjects with known poorly controlled diabetes (HbA1c > 9.0%), hyperthyroidism or thyroid insufficiency, Cushing's syndrome, or adrenal insufficiency 10. Subjects with known milk allergy or lactose intolerance 11. Other conditions that investigator considers subject is ineligible to participate in the study |
Country | Name | City | State |
---|---|---|---|
Taiwan | Veteran General Hospital-Taipei | Taipei |
Lead Sponsor | Collaborator |
---|---|
Orient Europharma Co., Ltd. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of subjects achieving clinically meaningful improvement in Increment = 3% in bone-free lean body mass (unit: kilogram) at 12 weeks after baseline | Bone-free lean body mass will be assessed by measured by dual- energy X-ray absorptiometry. An increment of = 3% from baseline after 12 weeks of intervention will be regarded as clinically meaningful improvement. | 12 weeks | |
Primary | The proportion of subjects achieving clinically meaningful improvement in Increment = 3% in 30-sec chair stand test (unit: number of stand) at 12 weeks after baseline | The score is the total number of stands within 30 seconds. | 12 weeks | |
Primary | The proportion of subjects achieving clinically meaningful improvement in Increment = 3% in strength of hand grip (unit: kilogram) at 12 weeks after baseline | Strength of hand grip will be assessed by Smedlay's DynamoMeter TTM Tokyo Japan. An increment of = 3% from baseline after 12 weeks of intervention will be regarded as clinically meaningful improvement. | 12 weeks | |
Secondary | Mean change in bone-free lean body mass at 4 and 12 weeks after baseline | Bone-free lean body mass will be assessed by measured by dual- energy X-ray absorptiometry. | 12 weeks | |
Secondary | Mean change in 30-sec chair stand test at 4 and 12 weeks after baseline | The score is the total number of stands within 30 seconds. | 12 weeks | |
Secondary | Mean change in 6-meter walk test at 4 and 12 weeks after baseline | The 6MWT measures the walking speed an individual is able to walk over a total of six meters on a hard, flat surface at their usual pace. | 12 weeks | |
Secondary | Mean change in short physical performance battery (SPPB) score at 4 and 12 weeks after baseline | including Balance test, Gait speed test, Chair stand test | 12 weeks | |
Secondary | Mean change in strength of hand grip at 4 and 12 weeks after baseline | Strength of hand grip will be assessed by Smedlay's DynamoMeter TTM Tokyo Japan. | 12 weeks | |
Secondary | Mean change in intramuscular fat assessed by MRI at 12 weeks after baseline | Intramuscular fat will be assessed using the magnetic resonance images (MRI) at baseline and Week 12 for 32 subjects. | 12 weeks | |
Secondary | Adverse events | Adverse events | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04207359 -
Effects of Creatine Supplementation in Breast Cancer Survivors
|
N/A | |
Enrolling by invitation |
NCT05215964 -
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
|
||
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Completed |
NCT05531305 -
Longitudinal Changes in Muscle Mass After Intensive Care
|
N/A | |
Completed |
NCT04597983 -
Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists
|
N/A | |
Completed |
NCT01292395 -
Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency
|
N/A | |
Completed |
NCT00755638 -
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
|
Phase 1 | |
Completed |
NCT04546048 -
The Early Strength Training Program in Post-transplant Liver Cases
|
N/A | |
Recruiting |
NCT05570474 -
Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery
|
N/A | |
Completed |
NCT05497960 -
Vivo Prediabetes Study: Online, Live, and Interactive Strength Training for Older Adults With Prediabetes
|
N/A | |
Completed |
NCT04422665 -
Preventing Bed-rest Induced Muscle Loss in the Elderly
|
N/A | |
Completed |
NCT05088304 -
GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
|
||
Completed |
NCT03400046 -
The Correlation Between Nutrients and Muscle Mass
|
N/A | |
Completed |
NCT01894737 -
The Effect of Creatine on Muscle Loss
|
N/A | |
Completed |
NCT01714479 -
Skeletal Muscle Response to Amino Acids and Load Carriage Exercise
|
N/A | |
Completed |
NCT05072652 -
Short Term Immobilization of the Lower Limb
|
N/A | |
Completed |
NCT04661618 -
A Randomized-Control Study of Gym Tonic's Community Based Strength Training Intervention.
|
N/A | |
Completed |
NCT05009654 -
The Effect of Leucine on Carnitine Transport to Skeletal Muscle
|
N/A | |
Recruiting |
NCT05795556 -
Biomarkers of Sarcopenia and Frailty in Geriatric Patients
|
||
Completed |
NCT04151108 -
Biomarkers for Length of Hospital Stay and Loss of Muscle Mass and Function in Old Medical Patients
|